WEGOVY vs OZEMPIC

What each one is approved for

This is the difference that decides everything else, including which one a prescriber can write and whether a plan will pay for it. OZEMPIC’s label opens with glycemic control:

Its other two uses start from the same place: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Every one of the three names type 2 diabetes. There is no weight-loss use on the OZEMPIC label at all.² The FLOW trial discussion explains the kidney population and outcome behind that distinction.

WEGOVY’s label starts somewhere else:

The condition there is obesity or overweight rather than diabetes. Its second use is reducing excess body weight and maintaining that reduction long term, in adults and in patients aged 12 and older, and its third is noncirrhotic MASH with moderate to advanced liver fibrosis in adults. Which of those a prescription is written for is what a plan reads, and the WEGOVY coverage page follows that through.¹

Side by side

The two ladders start identically and end in different places. OZEMPIC climbs 0.25 to 0.5 mg after four weeks, then to 1 mg and, if more glycemic control is needed, to 2 mg after at least four weeks on 1 mg. WEGOVY keeps going: 1.7 mg at weeks 13 to 16 and 2.4 mg from week 17. The WEGOVY dose schedule sets its version out in full.^1,2

The side-effect numbers are not comparable, and the reason matters

WEGOVY’s label reports nausea in 44% of people against 16% on placebo. OZEMPIC’s reports 20.3% at 1 mg against 6.1%. It is tempting to read that as one drug being twice as hard to take, and the labels themselves rule that reading out: the trials were run in different populations at different doses, and each label prints a sentence saying rates from one drug’s trials cannot be directly compared with another’s.^1,2

Each table with its own population attached is on the WEGOVY side effects page and the OZEMPIC one.

Not both at once

One instruction appears on the WEGOVY label in plain words, and it is the one people miss when they are changing from one to the other:

A switch between them is a prescriber’s decision about dose as well as brand, because the ladders do not line up: 2 mg is the top of one and a step on the way up the other.

What they cost is a third difference

The published prices are not the same, and neither is what Medicare does with them. Novo Nordisk publishes $349 a month for the WEGOVY pen after an introductory period, and $349 or $499 for OZEMPIC depending on dose. Eligible Medicare patients can get WEGOVY at $50 a month through the GLP-1 Bridge program, whose covered list does not include OZEMPIC.

Both sets of figures, with the dates they were read, are on the WEGOVY price page and the OZEMPIC one.

Questions